Pluri Inc. Form PRER14A: Revised preliminary proxy statement
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2020-05-18: Form PRER14A; Description AMENDED PRELIMINARY 14A.; Document ea122017-prer14a_pluristem.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2020-05-18 | PRER14A | AMENDED PRELIMINARY 14A. | ea122017-prer14a_pluristem.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |